Abstract: Objective: To explore the clinical value and rational choice for combined therapy of cervical cancer. Methods: A total of 116 patients have received the combined therapy. The prognostic factors and treatment results were analyzed. Results: 1) The 3-year survival rate of cervical cancer with stage Ⅰb, Ⅱa and Ⅱb, treated with surgery alone, was 87.5%, 60% and 50%, respectively. And the 3-year survial rate of cervical cancer with stage Ⅰb, Ⅱa, and Ⅱb, treated with preoperative radiotherapy and surgery, was 87.5%, 85.7% and 81.8%, and those with postoperative radiotherapy was 100%, 75% and 75% respectively. The 3-year survial rate of stage Ⅲ and Ⅳ cervical cancer with radiotherapy and chemotherapy was 52.6% and 0%, respectively. The difference of the four groups was statically significant. (P<0.01). 2) The clinical stages and postoperative pelvic lymph-node metastasis were the important prognostic factor for the patients with cervical cancer. The 3-year survival rate was 95.7% with no lymphatic metastasis, 75.9% with 1~2 positive nodes and 56.3% with more than 2 positive nodes. Conclusions: The near-term efficacy with combined therapy is better than that with surgery alone, the preoperative radiotherapy can raise the removal rate, but has little increase in the postoperative complications. The number of positive nodes in the pelvis relates to the survival rate. For the patients who had high-risk factor after the operation, adjuvant therapy should be given.